GSK's RSV Vaccine Demonstrates Long-Lasting Protection Across Multiple Seasons

In a significant development for public health, GlaxoSmithKline (GSK) has announced that its respiratory syncytial virus (RSV) vaccine shows promising durability in its protective effects, extending its efficacy over a remarkable three seasons. This finding is pivotal as RSV poses a substantial risk, particularly for infants and elderly populations, leading to severe respiratory illnesses and hospitalizations each year.

Continue reading